Shareholder Alert: Ademi LLP investigates whether Cerevel Therapeutics has obtained a Fair Price in its transaction with AbbVie

MILWAUKEE, Dec. 6, 2023 /PRNewswire/ -- Ademi LLP is investigating Cerevel (NASDAQ: CERE) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie.

Click here to learn how to join the https://www.ademilaw.com/case/cerevel-therapeutics or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Cerevel stockholders are expected to receive only $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion The transaction agreement unreasonably limits competing transactions for Cerevel by imposing a significant penalty if Cerevel accepts a competing bid. Cerevel insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Cerevel's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Cerevel common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/cerevel-therapeutics.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP